You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Protective efficacy against culture-confirmed cholera of several risk factors

From: Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial

  B/B a B/T b T/T c
  Full d Outbreak-free e Full Outbreak-free Full Outbreak-free
  1-HR f PH test g 1-HR PH test 1-HR PH test 1-HR PH test 1-HR PH test 1-HR PH test
Vaccine efficacy
 ages 1 to <5 years 0.45* 0.970 0.38 0.351 0.34 0.250 0.38 0.417 0.47* 0.931 0.44* 0.780
 ages 5 to <15 years 0.67** 0.016 0.84** 0.617 0.71** 0.052 0.85** 0.806 0.59** 0.028 0.72** 0.217
 ages 15 years and older 0.74** 0.008 0.69** 0.023 0.73** 0.025 0.69** 0.050 0.73** 0.058 0.71** 0.046
Participant age
 1 to <5 years (ref) 0.0   0.0   0.0   0.0   0.0   0.0  
 5 to <15 years 0.69** 0.088 0.65** 0.011 0.74** 0.069 0.78** 0.249 0.77** 0.317 0.80** 0.542
 15 years and older 0.81** 0.000 0.80** 0.000 0.88** 0.011 0.89** 0.043 0.89** 0.061 0.89** 0.095
Ward of residence
 ward 29 (ref) 0.0   0.0   0.0   0.0   0.0   0.0  
 ward 30 0.40** 0.000 0.16 0.102 0.39** 0.000 0.15 0.209 0.39** 0.000 0.15 0.243
 ward 33 0.07 0.979 -0.02 0.610 0.07 0.941 -0.01 0.719 0.07 0.755 -0.01 0.751
Large cluster -0.61 0.382 -0.43 0.026 -0.60 0.403 -0.43 0.023 -0.60 0.384 -0.42 0.025
Own house 0.24 0.189 0.34* 0.549 0.24 0.351 0.34* 0.668 0.24 0.367 0.35* 0.715
Stable occupation 0.27 0.644 0.27 0.539 0.27 0.628 0.27 0.583 0.27 0.527 0.27 0.560
High income 0.32** 0.662 0.38** 0.125 0.32** 0.784 0.38** 0.109 0.32** 0.954 0.38** 0.121
Far from water -0.31 0.013 -0.09 0.476 -0.31 0.025 -0.08 0.627 -0.31 0.044 -0.09 0.683
Global test h   0.000   0.003   0.004   0.312   0.004   0.233
Log lik ratio i     106     122     118
  1. aboth vaccine and age effect are estimated for age group at baseline
  2. bvaccine effect is estimated for age group at baseline, age effect is estimated using time-dependent age groups
  3. cboth vaccine effect and age effect are estimated using time-dependent age groups
  4. dall participants were included
  5. eparticipants with events during March–April 2010 were excluded
  6. f1-hazard ratio, which can be interpreted as the protective efficacy for the vaccine effect. Significant terms (p< 0.05) are marked with * and highly significant terms (p< 0.01) are marked with **
  7. gp from test of proportional hazards (PH) assumption
  8. hglobal test of proportional hazards assumption
  9. ilog likelihood ratio relative to a Cox model with no covariate